Combining targeted therapies for advanced prostate cancer treatment
PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer
This study is looking at new treatment options for men with advanced prostate cancer that doesn't respond to hormone therapy, using a combination of special drugs that target the cancer while trying to protect healthy cells, with the hope of helping patients live longer and feel better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10508057 on NIH RePORTER |
What this research studies
This research investigates the use of combination therapies involving radiolabeled prostate-specific membrane antigen inhibitors (PSMAi) and alpha-emitting agents to treat metastatic castration-resistant prostate cancer (mCRPC). The approach focuses on utilizing high linear energy transfer (LET) alpha-particles, which are believed to be more effective at targeting resistant tumors while minimizing damage to healthy bone marrow. By exploring these innovative therapies, the research aims to improve survival rates and reduce side effects for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide more effective treatment options for patients with advanced prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous studies have shown promise with similar approaches using radiolabeled therapies, indicating potential for success in this novel combination strategy.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Zalutsky, Michael Rod — Duke University
- Study coordinator: Zalutsky, Michael Rod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.